Biomemory

What Biomemory does

Biomemory is a Paris-headquartered biotechnology company, founded in 2021, that develops DNA-based molecular data storage appliances engineered for enterprise and government data center environments. The company's core platform consists of two integrated components: the DNA Data Storage Server, a rackable appliance with an S3-compatible interface, modular architecture, and industrialized end-to-end write/store/read processes; and the DNA Card, a proprietary synthetic DNA storage medium offering up to 150 years of retention and readability, ultra-low energy consumption at rest, biosecure air-gapped design, and claimed enterprise-grade resilience beyond 10E-16 UBER. Underlying technology includes proprietary enzymatic DNA block assembly, supplemented in 2026 by acquired Catalog Technologies capabilities in high-speed DNA printing, high-throughput reading, and molecular computing.

Biomemory serves large-scale enterprise data centers, regulated and high-security organizations (national archives, healthcare records, genomic data), and cybersecurity-sensitive government and defense customers. Named deployments and engagements include Thales (national security and cybersecurity), SICPA (identity security), CNES (French space agency), and Bordeaux-Métropole (municipal archival). The company pursues an enterprise field sales motion with long deployment cycles extending into 2030-2031.

The business model spans three streams: hardware sales of DNA Data Storage Servers and DNA Cards; managed services across Services, Managed, and Deployed models; and recurring revenue from value-added software features such as Search and Compute. Pricing is not publicly disclosed; the company's economic narrative rests on claimed 20x TCO reduction over 10 years and 10x footprint reduction versus traditional cold storage solutions. Distribution is direct enterprise sales supplemented by a strategic OEM-style integration with Scality, which embeds Biomemory's DNA tier into Scality's object storage infrastructure. The company maintains its Paris headquarters and a Boston regional office acquired through the Catalog Technologies transaction, targeting a commercial data center deployment in H2 2026 and exabyte-scale capacity by 2030.

Name

Biomemory

Legal name

Biomemory

Website

https://biomemory.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Biomemory builds DNA-based molecular data storage appliances for enterprise and government data centers, offering rackable servers and synthetic DNA Cards with 150-year retention, S3-compatible integration, and claimed 20x TCO reduction versus traditional cold storage.

Ownership category

akta.pro rank

Product category

Enterprise Data Storage Hardware

NAICS

Computer Storage Device Manufacturing (334112), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Computer Storage Devices (3572), Services-Prepackaged Software (7372)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• DNA data storage
• Molecular data storage
• Cold storage appliances
• Data center storage
• Long-term archival storage

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. DNA Data Storage Hardware: Sale of DNA data storage servers and DNA Card appliances for data center environments. Hardware designed for rackmount deployment with modular architecture enabling seamless hardware upgrades and long-term compatibility
2. Managed Services: Managed service offerings supporting various business models including Services, Managed, and Deployed deployment options with progressive feature additions
3. Enterprise Software Features: Additional value-added functionalities such as Search and Compute capabilities delivered as feature upgrades within the molecular storage platform

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Biomemory develops IT-friendly DNA Data Storage servers and DNA Card media for data center environments. The platform translates binary digital content into synthetic DNA strands stored in rackable appliances, providing an ultra-durable, energy-efficient cold storage tier with up to 150-year retention, S3-compatible integration, and air-gapped biosecurity.

Product overview

Biomemory offers a unified DNA data storage platform consisting of the DNA Data Storage Server as the core hardware appliance and DNA Card as the proprietary storage medium. The DNA Card slots into the DNA Data Storage Server, which provides the industrialized end-to-end write/store/read processes and interoperable S3 interface for seamless integration into existing data center multi-tier architectures. The platform targets cold storage and long-term archival applications with claims of 150-year retention, enterprise-grade resilience, and 20x TCO reduction versus traditional cold storage solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• DNA Data Storage Server Rackable DNA data storage server designed for data center environments, featuring an interoperable S3 interface, modular architecture, and end-to-end write/store/read processes for molecular data storage. Targeted at enterprise and government customers needing long-term cold storage and high-security archival.
• DNA Card Synthetic DNA storage medium contained in a card format that slots into the DNA Data Storage Server, providing long-term data retention (up to 150 years), ultra-low energy consumption at rest, biosecure air-gapped protection, and scalable rack-level density.

Quantifiable outcome

• Up to 20x TCO reduction over 10 years vs traditional cold storage solutions
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• ScalitycoreTechnology or Integration · 2 June 2026Strategic partnership to develop DNA-based long-term archival storage solutions integrated as a secure, ultra-long-term archival tier within Scality's existing object storage infrastructures. Targets 150-year data retention for applications including national archives and healthcare records. Marks Scality's entry into DNA archival storage.
• Catalog TechnologiesflagshipStrategic or Co-development Partner · 14 April 2026Asset acquisition combining Catalog's scalable high-speed printing and high-throughput reading capabilities with Biomemory's enzymatic DNA block assembly. Enables launch of commercial DNA data storage solution in H2 2026 and establishes North American footprint with Boston flagship office for R&D, production, and customer support.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Catalog Technologies: Boston-based DNA data storage and computing pioneer whose assets were acquired by Biomemory in March 2026. Directly comparable technology stack (DNA print, store, read) and was the most direct competing commercial DNA storage venture prior to acquisition.
• Iridia: Emerging DNA data storage company developing semiconductor-based enzymatic synthesis for archival storage. Targets the same DNA-as-storage end-market and represents the most direct active competitor to Biomemory's rackable appliance approach.

Broad incumbents

• Twist Bioscience: Public DNA synthesis company with a DNA data storage division and silicon-based synthesis platform. Comparable as a scaled DNA synthesis incumbent with adjacent storage activity, broader synthetic biology portfolio, and significantly greater capital resources.
• Quantum Corporation: Long-established enterprise tape and cold storage vendor whose LTO-based products are the primary incumbent solution for the long-term archival workloads Biomemory targets. Directly comparable customer base and use cases even though the underlying storage medium differs.
• Spectra Logic: Enterprise tape archive specialist serving media & entertainment, government, and research customers. Comparable as the de facto incumbent for 30+ year cold/archival retention tiers that Biomemory's 150-year claim is designed to disrupt.
• IBM: Co-developer of the LTO tape standard and operator of large hyperscale data center infrastructure. Comparable both as an incumbent cold-storage technology provider and as a potential strategic acquirer or partner for molecular storage technology.
• Seagate: Mass-volume HDD manufacturer pushing HAMR-based high-density drives for cold and warm storage tiers. Directly competes for the same enterprise storage budgets and continues to drive down cost per terabyte in the cold storage tier.
• Western Digital: Major HDD and enterprise storage vendor whose high-capacity drives are widely deployed in data center cold tiers. Comparable as an incumbent competing on cost-per-terabyte and density against Biomemory's molecular alternative.

Emerging players

• DNA Script: Enzymatic DNA synthesis company whose underlying synthesis chemistry is comparable to Biomemory's enzymatic block assembly. Relevant as a potential supplier or competitor in the enzymatic DNA synthesis value chain underpinning DNA storage.

Others

• Scality: Object storage software vendor with whom Biomemory has a strategic partnership to integrate DNA storage as an archival tier. Adjacent participant that serves as both distribution channel and a comparable in the enterprise object storage ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biomemory

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomemory